El futuro en la prevención de la tuberculosis

Medicina Clinica

Volumn 110, Issue 10, 1998, Pages 391-397

  García Rodríguez, José Francisco ^a   Aguado García, José María ^b,c  

^a Universidad de La Coruña   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BCG VACCINE; CIPROFLOXACIN; CYTOKINE; DAPSONE; IMMUNOMODULATING AGENT; ISONIAZID; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; IMMUNOLOGICAL ADJUVANT;

DRUG EFFICACY; DRUG MIXTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; MYCOBACTERIUM TUBERCULOSIS; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL; FORECASTING;

ADJUVANTS, IMMUNOLOGIC; FORECASTING; HUMANS; TUBERCULOSIS;

EID: 0032554594     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (175)

1. Brudney K, Dobkin J. Resurgent tuberculosis in New York City Am Rev Respir Dis 1991; 144: 745-749.
2. Eriki PP, Okwera A, Aisu T, Morrissey AB. Ellner JJ. Daniel TM. The influence of human immunodeficiency virus infection on tuberculosis in Kampala, Uganda. Am Rev Respir Dis 1991; 143: 185-187.
3. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infectec persons - Florida and New York. 1988-1991. MMWR 1991; 40: 585-591.
4. Edlin BR. Tokars JI, Gnego MH. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N EnglJ Med 1992; 326: 1.514-1.521.
5. Grupode Estudiode Tuberculosis Resistente en Madrid. Estudio transversal multihospitalano de tuberculosis y resistencias en Madrid (octubre de 1993-abril de 1994). Med Clin (Barc) 1996: 106: 1-5.
6. Ellner JJ. Hinman AR Dooley SW, Fischl MA, Sepkuwitz KA, Goldbergei MJ et al. Tuberculosis Symposium: Emerging Problems and Promise. J Infect Dis 1993; 168: 537-551.
7. Small PM, Hopewell PC, Singh SP, Paz A, Personnet J, Ruston DC et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods N Engl J Med 1994; 330: 1.703-1.709.
8. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bnswnrth W et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1.710-1.716.
9. Small PM, Shafer RW, Hopewell PC, Singh SP. Murphy MJ. Desmond E et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328: 1.137-1.144.
10. Genewein A, Telenti A, Bernasconi C, Mordasini C, Weiss S. Maurer AM et al. Molecular approach to identifying route of transmiss on of tuber culosis in the community. Lancet 1993; 342: 841-844.
11. Frieden TR, Sterling T, Pablos-Méndez A. Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-526.
12. Bloch AB, Cauthen GM, Onorato IM, Dansbury KG, Kelly GD. Driver CR et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271: 665-671.
13. CDC. A strategic plan for the elimination of tuberculosis in the United States. MMWR 1989; 38: 1-25.
14. CDC. Screening for tuberculosis and tuberculosis infection in high-risk populations and the use of preventive therapy for tuberculosis infection in the United States: recommendations of the Advisory Committee for the Elimination of Tuberculosis. MMWR 1990; 39: 1-12.
15. Caminero Luna JA. Medidas básicas para et control de la tuberculosis en una comunidad. Med Clin (Barc) 1994; 102: 67-73.
16. Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections. Treatment of tuberculosis and tuberculosis infection in adults and children. Clin Infect Dis 1995; 21: 9-27.
17. Jan Geiseler P, Nelson KE, Crispen RG. Tuberculosis in physicians. Compliance with preventive measures. Am Rev Respir Dis 1987; 135: 3-9.
18. Fraser VJ, Kilo CM. Bailey TC, Medoff G, Dunagan WC, Screening of physicians for tuberculosis. Infect Control Hosp Ep demiol 1994; 15: 95-100.
19. Enarson DA, Grosset J, Mwinga A, Hershfield ES, O'Brien R, Cole S et al. The challenge of tuberculosis: statements on global control and prevention Lancet 1995; 346: 809-819.
20. Snider DE, La Montagne JR. The neglected global tuberculosis problem: a report of the 1992 World Congress on Tuberculosis J Infect Dis 1994; 169: 1.189-1.196.
21. Cynamon MH, Klemens SP. New antimycobacterial agents. Clin Chest Med 1989; 10: 335-364.
22. Bates JH. Tuberculosis chemotherapy. The need for new antituberculosis drugs is urgent Am J Respir Crit Care Med 1995; 151: 942-943.
23. García Rodríguez JF, Aguado García JM. Tratamiento de la tuberculosis: ayer, hoy y mañana. Med Clin (Barc) 1997; 108: 389-395.
24. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564.
25. Moulding TS, Redeker AG Kanel GC. Twenty isoniazid-associated deaths in one State. Am Rev Respir Dis 1989; 140: 700-705.
26. Bloch AB, Simone PM, McCray E, Castro KG. Preventing multidrug-resistant tuberculosis. JAMA 1996; 275: 487-489.
27. Lecoeur HF, Truffot-Pernot C, Grosset JH Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide Am Rev Respir Dis 1989; 140: 1.189-1.193.
28. Jabës D, Della Bruna C, Rossi R, Olliaro P, Effectiveness of rifabutin alone or in combination with isoniazid n preventive therapy of mouse tuberculosis. Antimicrob Agents Chemother 1994; 38: 2.346-2.350.
29. Livengood JR. Sigler TG, Foster LR, Bobst JG, Snider DE. Isoniazid-resistant tuberculosis A community outbreak and report of a rifampin prophylaxis failure. JAMA 1985; 253: 2.847-2.849.
30. Chapuis L, Ji B, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Grosset JH. Preventive therapy of tuberculosis with rifaoentine in immunocom petent and nude mice. Am J Resoir Crit Care Med 1994; 150: 1.355-1.362.
31. Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O'Brien RJ, O liaro P et al Effectiveness of rifampin. rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148: 1.541-1.546.
32. Miller B, Preventive therapy for tuberculosis. Med Clin North Am 1993; 77: 1.263-1.275.
33. A joint statement of the International Union Against Tuberculosis and Lung Disease (IUATLD) and the Global Programme on AIDS and the Tuberculosis Programme of the World Health Organization (WHO) Tuberculosis preventive therapy in HIV-infected individuals. Tuberc Lung Dis 1994; 75: 96-98.
34. Mazar-Stewart V, Nolan CM Results of a directly observed intermittent isoniazid preventive therapy program in a shelter for homeless men Am Rev Respir Dis 1992: 146: 57-60.
35. Halsey N, Coberly J, Atkinson J, Boulos R, Twice weekly INH for TB prophylaxis [resumen PB0681] Tenth International Conference on AIDS/International Conference on STD, Yokahama, 7-12 de agosto de 1994
36. Dutt AK, Moers D, Stead WW. Smear-and culture-negative pulmonary tuberculosis: four-months short-course chemotherapy Am Rev Respir Dis 1989; 139: 867-870.
37. Kapetaneas ST. Rapti A, Arapis I, Chrisiotis CHR. Anagnostopulo U. Short-term chemoprophylaxis. Experience in Grece. Am Rev Respir Dis 1990; 141: A437.
38. Geiter LJ, O'Brien RJ, Kopanoff DE. Short-course preventive therapy for tuberculosis. Am Rev Respir Dis 1990; 141: A437
39. Subcommittee of the Joint Tuberculosis Committee. Chemotherapy and management of tuberculosis in the United Kingdom; recommendations of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1990; 45: 403-408.
40. Hong Kong Chest Service/Tuberculosis Researcn Centre, Madras/British Medical Research Council. A Double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41
41. McNicol MW, Thomson H, Riordan JF, Forde E, Allen CJ. Antituberculous chemoprophylaxis with isoniazid-rifampicin. Thorax 1984; 39: 223-224.
42. Solera J, Martinez-Altaro E, Säez L, Serna E, Vergara LI. López E. Effectiveness of a short-course chemoprophylaxis (CP) of tuberculosis (TB) in HIV-seropositive and HIV seronegative intravenous drugs use's (IDUs). In 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, Florida 1994; 1183.
43. Pedro-Botet J, Gutiérrez J, Miralles R, Coll J, Rubiés-Prat J. Pulmonary tuberculosis in HIV-infected patients with normal chest radiographs. AIDS 1992; 6: 91-93.
44. De Cock KM, Grant A, Porter JD. Preventive therapy for tuberculosis n HIV-infected persons: international recommendations, research ard practice Lancet 1995; 345: 833-836.
45. Sterling TR, Brehm WT, Frieden TR. Isoniazid preventive therapy n areas of high isoniazid resistance. Arch Intern Med 1995; 155: 1.622-1.628.
46. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and ritampin: a meta-analysis. Chest 1991; 99: 465-471.
47. Grosset J. New experimental regimens for preventive therapy of tuberculosis. Bull Int Union Tuberc Lung Dis 1990/1991; 66: 15-16.
48. Greiter LJ. O'Brien RJ, Kopanoff DE. Short-course preventive therapy for tuberculosis. In World Conference on Lung Health (Supl 1) Am Rev Respir Dis 1990; 141 (part 2): A437.
49. Gracyk J. O'Brien RJ, Bek E. Nimerowska H, Geiter LJ. Assessment of rifampin-containing regimens for tuberculosis preventive therapy: preliminary results of a pilot study in Poland, In 1991 International Conference (Supl). Am Rev Respir Dis 1991; 143 (part 2): A119.
50. Magdorf K, Arizzi Rusche AF, Geiter LJ, O'Brien RJ, Wahn U. Short-course preventive therapy for tuberculosis: a pilot study of rifampin and rifampin-pyrazinamide regimens in children. In 1991 International Conference (Supl). Am Rev Respir Dis 1991; 143 (part 2); A119.
51. Hong Kong Chest Service/Tuberculosis Research Centre. Madras/British Medical Research Council A Controlled Trial of 2-months, 3-months and 12-months regimens of chemotherapy for sputum-smearnegative pulmonary tuberculosis Am Rev Respir Dis 1984; 130: 23-28.
52. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council A Controlled Trial of 3-months. 4-months and 6-montns regimens of chemotherapy for sputum-smearnegalive Results at 5 years. Am Rev Respir Dis 1989; 139: 871-876.
53. Grosset J. Present and new drug regimens in chemotherapy and chemoproohylaxis of tuberculosis. Bull Int Union Tuberc Lung Dis 1990; 65: 86-91.
54. Mitchison DA. Pyrazinamide in the chemoprophylaxis of tuberculosis. Am Rev Respir Dis 1991; 142: 1.467.
55. Kennedy N, Fox R, Uiso L, Ngowi FI, Gillespie SH. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis, J Antimicrob Chemother 1993; 32: 897-902.
56. Kennedy N, Fox R, Kisyombe GM, Saruni AOS, Uiso LO, Ramsay ARC et al Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tubercuosis. Am Rev Respir Dis 1993; 148: 1.547-1.551.
57. Chadwick M, Nicholson G. Gaya H. Brief report: combination chemotherapy with ciprofloxacin for infection with Mycobactenum tuberculosis in mouse models. Am J Med 1989; 87 (Supl 5A): 35-36.
58. Truffot-Pernot C, Ji B. Grossel J Activities of perfloxacin and ofloxacin agains: mycobacteria: in vitro and mouse experiments. Tubercle 1991. 72: 57-64.
59. Kohno S, Koga H, Kaku M, Maesaki S, Hara K. Prospective comparative study of ofloxacin or etambutol for the treatment of pulmonary tuberculosis. Chest 1992; 102: 1.815-1.818
60. Seydei JK, Schaper KJ, Rüsch-Gerdes S. Chemotherapy of TB. Experimental drugs and combination therapy Immunobiol 1994: 191: 569-577.
61. Rastor N, Goh KS. In vitro activity of the new difluorinated quinolore sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin Antimicrob Agents Chemother 1991; 35: 1.933-1.936.
62. Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155. sparfloxacin and ofloxacin. Antimicrob Agents Chemother 1993; 37: 1.259-1.263.
63. Opravil M, Pechëre M, Lazzarin A, Heald A, Rüttimann S, Ilen A et al. Dapsone/pyrimethamine may prevent mycobacterial disease in immunosuppressed patients infected with the numan immunodeficiency virus Clin Infect Dis 1995; 20: 244-249.
64. Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathar N, Bhatt AD, Rittel W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1993; 37: 183-186.
65. Wayne LG, Sramek HA, Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 2.054-2.058.
66. Strachan DP, Millard JFC, Maxwell JD, Preventive therapy for tuberculosis. Lancet 1995; 345: 1.439.
67. Lochner JD, Schneider DJ. The relationship between tuberculosis, vitamin D, potassium and AIDS, A message for South Africa? S Afr Med J 1994; 84: 79-82.
68. Passannante MR, Gallagher CT. Reichman LB. Preventive therapy for contacts of multidrug-resistant tuberculosis A delphi survey. Chest 1994; 106: 431-434.
69. Recomendaciones CDC MMWR: CDC, Management of persons exposed to multidrug resistant tuberculosis MMWR 1992; 41: 61-71.
70. Peloquin CA, Berning SE. Infection caused by Mycobacterium tuberculosis. Ann Pharmacother 1994; 28: 72-84.
71. Stevens JP, Daniel TM. Chemoprophylaxis of multidrug-resistant tuberculosis infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis. Chest 1995; 108: 712-717.
72. Horn DL, Hewlett D, Alfalla C, Peterson S, Opal SM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994; 330; 1.241
73. Koplar JP, Farer LS, Choice of preventive treatment for isoniazid-resistant tuberculous infection. Use of decision analysis and the delpni technique, JAMA 1980; 244: 2.736-2.740.
74. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A Double-blind placebo-controiled dinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
75. Cohn DL. Treatment and prevention of tuberculosis in HIV-infected persons. Infect Dis Clin North Am 1994; 8: 399-412.
76. Wadhawan D, Hira S, Mwansa N, Sunkutu R, Adera T, Perine P, Preventive tuberculosis chemotherapy with isoniazid (INH) among patients infected with HIV-1. Ninth International Conference on AIDS in affiliation with the Fourth STD World Congress [resumen PO-B07-1114]. Berlin, 6-11 de junio de 1993.
77. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992; 268: 504-509.
78. Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E et al. A prospective study of the risk of tuberculosis among HIV-infected patients, AIDS 1993; 7: 1.345-1.349.
79. 2 regimen be extended for smear positive pulmonary tuberculosis in HIV-1 infected patients? [Resumen 3]. 28th World Congress of IUATLD/UICTMR. Mainz, 14-17 de junio de 1994.
80. Sepkowitz KA, Raffalli J. Tuberculosis at the end of the twentieth century. Eur J Clin Microbiol Infect Dis 1994; 13: 902-907.
81. Wallis RS, Vjecha M, Amir-Tahmasseb M, Okwera A, Byekwaso F, Nyole J et al Influence of tuberculosis on HIV: enhanced cytokine expression and elevated beta-2-microglobulin in HIV-1 associated tuberculosis. J Infecl Dis 1993; 167: 43-48.
82. Whalen C, Horsburgh CR, Hom D, Lahart C, Sirnberkoff M, Ellner J Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Crit Care Med 1995; 151: 121-135.
83. Vidai SM, Malo D, Vogan K, Skamene E, Gros P, Natural resistance to infection with intracellular parasites: isolation of a candidate for BCG. Cell 1993; 73: 469-485.
84. Marcn Ayuela P. ¿Puede acortarse la quimioprofilaxis de la tuberculosis? A la búsqueda de una quimioprofilaxis corta de la tuberculosis. Arch Bronconeumol 1991; 27: 210-213.
85. De Vries R, Old BCG replaced by new vaccine? Human leukocyte antigens (HLA) and mycobacterial disease. Bull Int Union Tuberc Lung Dis 1990; 65: 30-31.
86. Gangadharam PRJ, Ashtekar DR, Farhi DC, Wise DL. Sustained release ol isomazid in vivo from a single implant of a biodegradable polymer. Tuberde 1991; 72: 115-122.
87. Gangadharam PRJ, Kailasam S, Srinivasan S, Wise DL. Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers. J Antimicrob Chemother 1994; 33: 265-271.
88. O'Brien RJ, Snider DE Tuberculosis drugs - old and new. Am Rev Respir Dis 1985; 131: 309-311.
89. Swenson CE, Stewart KA, Hammett JL, Fitzsimmons WE, Ginsberg RS. Pharmacokinehcs and in vivo activity of liposome-encapsulated gentamicin. Antimicrob Agents Chemother 1990; 34: 235-240.
90. Orozco LC, Quintana FO, Beitrán RM, Moreno I, Wasserman M, Rodriguez G. The use of rifampicin and isoniazid entrapped in liposomes for the treatment of murine tuberculosis. Tubercle 1986; 67: 91-97.
91. Klemens SP, Cynamon MH, Swenson CE, Ginsberg RS. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1990; 34: 967-970.
92. Koga H, Miyazaki V, Kohno S, Hara K. A drug delivery system and biological response modifiers for the treatment of mycobacterial infection [resumen]. Kekkaku 1994; 69: 113-118.
93. Agarwal A, Kandpal H, Gupta HP, Singh NB. Gupta CM. Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice. Antimicrob Agents Chemother 1994; 38: 588-593.
94. Cynamon MH, Klemens SP, Swenson CE. TLC G-65 in combination with other agents in the therapy of Mycobacterium avium infection in beige mice. J Antimicrob Chemother 1992; 29 693-699.
95. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and anhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85: 6.949-6.953.
96. Iseman M, Edberg SC, Ellner JJ, Hadler J, Hand WL, Kubica GP et al. Improving methods for prevention of disease among the infected. Am Rev Respir Dis 1986; 134: 413-414.
97. Dannenberg AM. Roles of cytotoxic delayed-type hipersensity and macrophage-activity cell mediated immunity in the pathogenesis of tuberculosis, Immunobiology 1994; 191: 461-473
98. Rook GAW, Hernández-Pando R. T cell helper types and endocrines in the regulation of tissue-demaging mechanisms in tuberculosis, Immunobiology 1994; 191: 478-492.
99. Stanford JL, Stanford CA. Immunotherapy of tuberculosis with Mycobacterium vaccae NCTC 11659. Immunobiology 1994; 191; 555-563.
100. Iseman MD. Treatment of multidrug-resistanl tuberculosis. N Eng J Med 1993; 329: 784-791.
101. ACCP/ATS Consensus Conference, Institutional control measures for tuberculosis in the era of multiple drug resistance. Chest 1995; 108: 1.690-1.710.
102. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. En: Bloom BR, editor. Tuberculosis, pathogenesis, protection and control. Washington: American Society of Microbiology, 1994; 531-557.
103. Fine PEM, Sterne JAC, Pönnighaus, Rees RJW Delayed-type hypersensitivity, mycobactenal vaccines and protective immunity. Lancet 1994; 344: 1.245-1.249.
104. Clemens J, Brenner R, Rao M. Tafari N, Lowe C. Evaluating new vaccines for developing countries Efficacy or effectiveness? JAMA 1996; 275: 390-397.
105. Lugosi L. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology. A review. Tuberc Lung Dis 1992; 73: 252-261.
106. Collins FM. Antituberculous immunity: new solutions to an old problem. Rev Infect Dis 1991; 13: 940-950.
107. Weissler JC. Southwestern Internal Medicine Conference: Tuberculosis-Immunopathogenesis and Therapy. Am J Med Sci 1993; 305: 52-65.
108. Comstock GW. Field trials of tuberculosis vaccines: how could we have done them better? Control Clin Trials 1994; 15: 247-276.
109. Johnson H, Lee B, Doherty E, Kelly E, McDonnell T. Tuberculin sensitivity and the BCG scar in tuberculosis contacts Tuberc Lung Dis 1995; 76: 122-125.
110. Kawamura I, Tsukada H, Yoshikawa H, Fujita M, Nomoto K, Mitsuyama M. IFN-gamma-producing ability as a possible marker for the protective T cells against Mycobacterium bovts BCG in mice. J Immunol 1992; 148: 2.887-2.893.
111. Gheorghiu M, The present and future role of BCG vaccine in tuberculosis control. Biologicals 1990; 18: 135-141.
112. Pithie AD, Rahelu M, Kumararatne DS, Drysdale P, Gaston JSH, Iles PB et al. Generation of cytolytic T cells in individuals infected by Mycobacterium tuberculosis and vaccinated with BCG. Thorax 1992; 47: 695-701.
113. Hess J, Kaufmann SHE, Vaccination strategies against intracellular microbes. FEMS Immunol Med Microbiol 1993; 7: 95-103.
114. Flynn JL, Goldstein MM, Trietod KJ, Koller B, Bloom BR. Major histocompatibility complex class l-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992; 89: 12.013-12.017.
115. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271: 698-702.
116. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 1.339-1.345.
117. Cirillo JD, Stover CK, Bloom BR, Jacobs WR, Barletta RG. Bacterial vaccine vectors and bacillus Calmette-Guérin. Clin Infect Dis 1995; 20: 1.001-1.009.
118. Bretscher PA. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy Immunol Today 1992; 13: 342-345.
119. Bretscher PA. Prospects for low dose BCG vaccination against tuberculosis, Immunobiology 1994; 191: 548-554.
120. Dhillon J, Mitchison DA Effect of vaccines in a murine model of dormant tuberculosis, Tuberc Lung Dis 1994; 75: 61-64.
121. Fine PEM, Rodrigues LC. Modern vaccines. Mycobacterial diseases. Lancet 1990; 335: 1.016-1.020.
122. Kemp EB, Belshe RB, Hoft DF Immune responses stimulated by percutaneous and intradermal BCG vaccination. Abstracts of the 35th ICAAC. San Francisco, 17-20 de septembre de 1995; G24: 162.
123. Al-Kassimi FA. Al-Hajjaj MS, Al-Orainey IO, Bamgboye EA. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? Am J Respir Crit Care Med 1995; 152: 1.575-1.578.
124. Weltman AC, Rose DN. The safety of bacille Caimette-Guérin vaccination in VIH infection and AIDS. AIDS 1993; 7: 149-157.
125. CDC Use of BCG vaccines in the control of tuberculosis: a joint statement by the ACIP and the Advisory Committee for Elimination of Tuberculosis, MMWR 1988; 37: 663-664, 669-675.
126. Orme IM, Miller ES, Roberts AD, Furney SK, Griffin JP, Dobos KM et al. T Iymphocites mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. Evidence for different kinetics and recognition of a wide spectrum of protein antigens. J Immunol 1992; 146: 189-196.
127. Andersen P, Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994; 62: 2.536-2.544.
128. Andersen P, Askgaard D, Ljungqvist L, Bentzon MW, Heron I. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 1991; 59: 1.558-1.563.
129. Andersen P. The T cell response to secreted antigens of Mycobacterium tuberculosis, Immunobiology 1994; 191: 537-547.
130. Stover CK, De la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT et al. New use of BCG for recombinant vaccines. Nature (Lond) 1991; 351: 456-460
131. Barnes PF, Mehra V, Rivoire B, Fong SJ, Brennan PJ, Voegtline MS et al Immunoreactivity of a 10-kDa antigen of Mycobacterium tuberculosis. J Immunol 1992; 148: 1.835-1.840.
132. Havlir DV, Wallis RS, Boom WH, Daniel TM, Chervenak K, Ellner JJ. Human immune response to Mycobacterium tuberculosis antigens Infect Immun 1991; 59: 665-670.
133. Boesen H, Nybo Jensen B, Wilcke T, Andersen P. Human T-Cell responses to secreted antigen fractions of Mycobacterium tuberculosis. Infect Immun 1995; 63: 1.491-1.497.
134. Orme I. Processing and presentation of mycobacterial antigens: implications for the development of a new improved vaccine for tuberculosis control. Tubercle 1991; 72: 250-252.
135. Zimmerman D, Elliott D, Rosenthal K. The use of peptide heteroconjugates to prime Th1 or Th2 activity to an eoitope of M. tuberculosis. Abstracts of the 35th ICAAC. San Francisco, 17-20 de septembre de 1995: G75; 171.
136. Donnelly-Wu MK, Jacobs WR Jr, Hatfull GF. Superinfection immunity of mycobacteriophage L5: applications for genetic transformation of mycobacterla. Mol Microbiol 1993; 7: 407-417.
137. Singh IG, Mukherjee R, Talwar GP. Resistance to intravenous inoculation of Mycobactenum tuberculosis H37Rv in mice of deifferent inbrec strains fo lowing immunization with a leprosy vaccine based on Myco-bacterium w. Vaccine 1991; 9: 10-14.
138. Standford JL, Rook GAW, Bahr GM, Dowlati Y, Ganapati R, Ghazi Said K et al. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 1990; 8: 525-530.
139. Etemadi A, Farid R, Stanford JL. Immunotherapy for drug-resistant tuberculosis. Lancet 1992; 340: 1.360-1.361.
140. Stanford JL, Grange JM. The promise of immunotherapy for tuberculosis. Respir Mec 1994; 88: 3-7.
141. Stanford JL, Grance JM. New concepts for the control of tuberculosis in the twenty firts century. J R Coll Physicians (Lond) 1993; 27: 218-223.
142. Stanford JL, Onyebujoh PC, Rook GAW, Grange JM, Pozniak A. Old plague, new plague, and a treatment for both? AIDS 1993; 7: 1.275-1.277.
143. Rook GA, Onyebujoh P, Wilkins E, Ly HM, Attiyah R. Bahr G et al. A longitudinal study of per cent agalactosyl IgG in tuberculosis patients receiving chemotherapy, with or without immunotherapy. Immunology 1994; 81: 149-154.
144. Hoskyns EW, Simpson H, Monk P. Use of the I tuberculin unit (TU) Mantoux test in the assessment of tuberculous infection in children following neonatal BCG vaccination. Thorax 1994; 49: 1.006-1.009.
145. De March-Ayuela P. Choosing and approariate criterion for true or false conversion in serial tuberculin testing. Am Rev Respir Dis 1990; 141: 815-820.
146. Roche PW, Triccas JA, Avery DT, Fifis T, Billman-Jacobe H, Britton WJ. Differential T Cell responses to mycobacteria-secreted proteins distinguish vaccination with bacille Calmette-Guérin from infection with Mycobacterium tuberculosis. J Infect Dis 1994; 170: 1.326-1.330.
147. Roche PW, Peake PW, Billman-Jacobe H, Doran T, Britton WJ. T-cell determinants and antibody binding sites onthe major mycobacterial secretory protein MPB59 of Mycobacterium bovis. Infect Immun 1994; 62: 5.319-5.326.
148. Tang D, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature (Lond) 1992; 356: 152-154.
149. Wang B, Ligen KE, Srikantan V, Agadjanyan MG, Dang K, Rafaeli Y et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 4.156-4.160.
150. Aldovini A, Young RA. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature (Lond) 1991; 351: 479-482.
151. Collins FM. The immune response to mycobacterial infection: development of new vaccines. Vet Microbiol 1994; 40: 95-110.
152. McDonnell WM, Askari FK. DNA vaccines. N Engl J Med 1996; 334: 42-45.
153. Colizzi V, Vismara D, D'Urso C, Mezzopreti MF, Lombardi G, Piccolella E et al. Analysis of Mycobacterium tuberculosis genoma and production of a recombinant protein containing specific B and T cell antigenic determinants-new approaches to second generation antituberculosis vaccines [resumen]. Erkr Atmungsorgane 1989; 172: 40-52.
154. Schurr E, Buschman E, Mato D, Gros P, Skamene E. Immunogenetics of mycobacterial infections: mouse-human homologes. J Infect Dis 1990; 161: 634-639.
155. Schraufnagel D. Clinical applications of soluble interleukin-2 receptor in granulomatous disease. Chest 1991; 99: 268-269.
156. Rydberg J, Miörner H, Chandramjki A, Lantz M. Assessment of a possible imbalance between tumor necrosis factor (TNF) and soluble TNF receptor forms in tuberculous infection of the central nervous system. J Infect Dis 1995; 172: 301-304.
157. Schauf V, Rom WN, Smith KA, Sampaio EP, Meyn PA. Tramontane JM et al. Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. J Infect Dis 1993; 168: 1.056-1.059.
158. Andersen PM, Hanson DC, Hasz DE, Hatet MR, Blazar BR. Ochoa AC. Cytokines in liposomes: preliminary studies with IL-1. IL-2, IL-6, GM-CSF and interferon-gamma. Cytokine 1994; 6: 92-101.
159. Appelberg R. Protective role of interferon gamma, tumor necrosis factor alpha and interleukin-6 in Mycobacterium tuberculosis and Mycobacterium avium infections, Immunobiology 1994; 191: 520-525.
160. Kamijo R, Le J. Snapiro D, Havell EA, Huang S, Aguet M et al. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with bacillus Calmette-Guérin and subsequent challenge with lipopolysaccharide. J Exp Med 1993; 178: 1.435-1.440.
161. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom B. An essential role for Interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2.249-2.254.
162. Parranchi P, De Carli M, Manetti R, Simonelli C, Sampognaro S, Piccinni MP et al. IL-4 and IFN (alfa and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cells clones. J Immunol 1992; 149: 2.977-2.983.
163. Denis M. Killing of Mycobacterium tuberculosis within human monocytes: activatior by cytokines and calcitriol. Clin Exp Immunol 1991; 84: 200-206.
164. Denis M, Ghadirian E. Granulocyte-macrophage colony-stimulating factors restricts growth of tubercle bacilli in human macrophages, Immunol Lett 1990; 24: 203-206.
165. Brown D, Fars M, Hilburger M, Zwilling BS. The induction of persistence of I-A expression by macrophages from Beg' mice occurs via a protein kinase C-dependent pathway. J Immunology 1994; 152: 1.323-1.331.
166. Barnes PF, Grisso CL, Abrams JS, Band H, Rea TH, Modlin RL. Gamma-delta T lymphocytes in human tuberculosis. J Infect Dis 1992; 165: 506-512.
167. Adams LB, Mason CM, Kolls JK, Scollard D, Krahenbuhl JL, Nelson S. Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus. J Infect Dis 1995; 171: 400-405.
168. Bermudez LEM, Young L. Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. Antimicrob Agents Chemother 1988; 32: 1.149-1.153.
169. Toossi Z, Sedor JR, Lapurga JP, Ondash RJ, Ellner JJ. Expression of functional interleukin 2 receptors by peripheral blood monocytes from patients with active pulmonary tuberculosis. J Clin Invest 1990; 85: 1.777-1.784.
170. Appelberg R, Castro AG, Pedrosa J, Minoprio P. Role of interleukin-6 in the induction of protective T cells during mycobacterial infections in mice. Immunology 1994; 82: 361-364.
171. Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995; 155: 2.515-2.524.
172. Holland SM, Eisenstein EM, Kuhns DB, Tuner ML, Fleisher TA, Strober W et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. N Engl J Med 1994; 330: 1.348-1.355.
173. Garcia Rodriguez JF, Vázquez Castro J, De Juan Prego J, Rodríguez Mayo M, Sesma Sánchez P, Gonzȧlez Moraleja J. Epidemiologie de la tuberculosis en El Ferrai. Med Clin (Barc) 1995; 104: 365-368.
174. CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities-1994. MMWR 1994; 43: 1-133.
175. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney B et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1.179-1.184.